The neonatal european study of inhaled steroids (neurosis): An eu-funded international randomised controlled trial in preterm infants by Bassler, D. (Dirk) et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Research Briefings 
 Neonatology 2010;97:52–55 
 DOI: 10.1159/000227294 
 The Neonatal European Study of Inhaled Steroids 
(NEUROSIS): An EU-Funded International 
Randomised Controlled Trial in Preterm Infants 
 Dirk Bassler a    Henry L. Halliday b    Richard Plavka c    Mikko Hallman d    
Eric S. Shinwell e, f    Pierre-Henri Jarreau g    Virgilio Carnielli h    John van den Anker i, j    
Matthias Schwab k, l    Christian F. Poets a 
 a  Department of Neonatology, University Children’s Hospital,  Tübingen , Germany;  b  Royal Maternity Hospital,
and Department of Child Health, Queen’s University,  Belfast , UK;  c  General Faculty Hospital in Prague,  Prague ,
Czech Republic;  d  Department of Pediatrics and Adolescence and Neonatal Research Laboratory,
Oulu University Hospital, University of Oulu,  Oulu , Finland;  e  Department of Neonatology, Kaplan Medical Center, 
Rehovot, and  f  Hebrew University,  Jerusalem , Israel;  g  Assistance Publique-Hôpitaux de Paris, Service de
Médecine Néonatale de Port-Royal and Université Paris Descartes,  Paris , France;  h  Department of Paediatrics,
Children’s Hospital, Azienda Ospedaliero-Universitaria,  Ancona , Italy;  i  Children’s National Medical Center,
 Washington, D.C. , USA;  j  Department of Paediatrics, Erasmus MC Sophia Children’s Hospital,  Rotterdam ,
The Netherlands;  k  Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology,  Stuttgart , and
 l  Department of Clinical Pharmacology, University Hospital Tübingen,  Tübingen , Germany
 
inflammatory properties, and early inhalation of cortico-
steroids may provide beneficial local effects on the lungs 
prior to development of a full inflammatory response 
with a lower risk of undesirable systemic side effects.
 Inhaled Postnatal Steroids  
 The efficacy of inhaled steroids to prevent BPD has 
already been investigated in several randomised trials, 
both in comparison with systemic steroids  [13] and with 
placebo  [14–20] . According to recent systematic reviews 
on inhaled drugs for the prevention and treatment of 
BPD, there are 7 fully published controlled trials in which 
infants were either randomised to inhaled steroids or pla-
cebo within 2 weeks of life  [21, 22] . However, these trials 
have not provided a definite answer to the question of 
best timing of inhalation of steroids. 
 Introduction 
 Survival of extremely low birth weight infants has im-
proved in recent decades, but bronchopulmonary dyspla-
sia (BPD) remains a major health care problem  [1] . BPD 
not only contributes to the mortality of preterm infants, 
but is also associated with impaired neurosensory devel-
opment in survivors  [2, 3] . Furthermore, a diagnosis of 
BPD has been associated with respiratory morbidity later 
in life  [4–8] . This puts an enormous burden not only on 
individual patients and their families, but also on collec-
tive health resources.
 Genetic background and antenatal environmental 
factors play an important, yet poorly defined role in the 
pathogenesis of BPD  [9, 10] . Central is the exposure of the 
developing lung to inflammation  [10–12] . Most infants 
that develop BPD encounter the first serious inflamma-
tory event early after birth  [12] . Corticosteroids have anti-
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 In 5 trials, inhaled corticosteroids were initiated at day 
3 of life or later  [14–18] . Among these trials is the largest 
randomised placebo-controlled trial (RCT) on inhaled 
corticosteroids for the prevention of BPD published to 
date that included 253 preterm infants  [14] . In this study, 
inhaled beclomethasone was initiated at an average of 5.5 
days and did not prevent BPD, but was associated with a 
reduced use of systemic glucocorticoid therapy and me-
chanical ventilation. 
 In the 6th study, therapy with inhaled fluticasone pro-
prionate was started in the first 24 h of life in 53 venti-
lated infants  [19] . Inhaled steroids resulted in a signifi-
cantly higher success rate for extubation within the first 
2 weeks of life and a more pronounced improvement in 
lung compliance. Six infants in the fluticasone group and 
12 in the placebo group either died or were oxygen depen-
dent at 36 postconceptional weeks, a difference that was 
not statistically significant.
 In the 7th study, a pilot study, the first dose of beclo-
methasone or placebo was initiated at birth in 47 preterm 
infants  [20] . This study also failed to show a statistically 
significant reduction in BPD rates at 36 weeks, but in-
haled steroids reduced the need for supplemental oxygen 
at 30 weeks. 
 Open Questions 
 Most of the studies mentioned above only included 
ventilator-dependent preterm infants  [14, 15, 17–20] , but 
BPD also develops in preterm infants who require rela-
tively little ventilatory support in the first few days of life 
 [23–25] . An RCT enrolling mechanically ventilated in-
fants and also those on continuous positive airway pres-
sure (CPAP) that investigates the efficacy and safety of 
very early inhalation of budesonide might therefore help 
to improve survival without BPD in preterm infants. The 
long-term safety and efficacy of inhaled steroids, how-
ever, has not been adequately studied  [22, 26] , and since 
early  systemic corticosteroids affect neurodevelopmental 
outcomes in preterm infants  [27, 28] , a new RCT of in-
haled budesonide should include a long-term follow-up.
 Summary of Study  
 The Neonatal European Study of Inhaled Steroids 
(NEUROSIS) is a randomised placebo-controlled, in-
ternational clinical trial. 850 infants of 23–27 weeks’ 
postmenstrual age (either mechanically ventilated or on 
CPAP) will be randomised during the first 12 h of life 
Birth
(gestation <28 weeks)
Infants mechanically ventilated or on
nasal ventilation/CPAP 
R R
12 h 
Budesonide BudesonidePlacebo Placebo
Primary outcome: BPD or death at 36 weeks’ gestational age
Major secondary outcome: neurodevelopment at 18–22 months
GA: 23 0/7–25 6/7 GA: 26 0/7–27 6/7
 Fig. 1. Diagram showing the study design 
for NEUROSIS. GA = Gestational age; R = 
randomisation. 
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to budesonide or placebo ( fig. 1 ). Study drugs will be 
administered via a spacer device and continued until 
infants no longer need either supplemental oxygen or 
positive pressure support or have reached a postmen-
strual age of 32 0/7 weeks regardless of ventilatory sta-
tus. The primary outcome of survival without BPD will 
be determined at 36 weeks’ postmenstrual age, and BPD 
will be defined according to the physiological definition 
 [29] . Study patients will be followed and neurodevelop-
mental outcomes assessed at a corrected age of 18–22 
months. 
 The severity of BPD according to 3 different defini-
tions will be determined as an exploratory analysis. Can-
didate genes related to absorption, distribution, metabo-
lism, and excretion of budesonide will be investigated in-
cluding pharmacokinetic data. Moreover, a sub-study on 
genetic susceptibility to BPD will be performed.
 NEUROSIS is funded by the European Union in its
7th framework program. Infants are planned to be ran-
domised starting from September 2009, and units are in-
vited to participate. The results of NEUROSIS will pro-
vide useful indications about the efficacy and safety of 
inhaled steroids in very preterm infants.
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